Exploring Myeloma Maintenance Therapy with Lenalidomide and Daratumumab Post-Autologous Stem Cell Transplant
Understanding the AURIGA Study on Myeloma Treatment
Ashraf Badros, MB, ChB, professor at the University of Maryland School of Medicine and director of the Multiple Myeloma Service, highlighted the significance of recent findings from the AURIGA study at the 21st International Myeloma Society's conference in Rio de Janeiro.
Comparison of Maintenance Therapies
The AURIGA study investigates the effect of combining daratumumab with lenalidomide in patients after undergoing autologous stem cell transplant (ASCT). Badros pointed out the need for trials to explore the optimal duration of maintenance therapy.
Significance of the Findings
- The AURIGA trial illustrates effective alternatives compared to older studies, specifically those not including lenalidomide in maintenance.
- Importantly, findings from trials like CASSIOPEIA further support the use of daratumumab post-transplant.
- Patient outcomes show improved MRD (Minimal Residual Disease) negativity and progression-free survival, vital metrics in multiple myeloma treatment.
These insights could reshape the landscape of maintenance therapy strategies for multiple myeloma, enhancing patient care.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.